Clinical Trials Logo
  1. Home
  2. Cancer of Cervix
  3. NCT04809727
  4. Details
NCT04809727 Clinical Trial

Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Cancer of Cervix Clinical Trial

— HSTH  

Official title:
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04809727
Other study ID # HistopathSTH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2017
Est. completion date January 31, 2021

Study information
Verified date April 2021
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Supracervical hysterectomy is widely common and had many complications either immediate or delayed. In these patients bleeding, infection, chronic pelvic pain are common. In these patients cervical biopsy was done and histopathological examinations were done to evaluate the pathology in these patients.

Description:

- Study design and settings: Cross sectional descriptive studies conducted from December 2017 till January 2021. - Patients: 80 patients with supracervical hysterectomy recruited at Tanta University Hospital, gynecology clinics will be recruited according inclusion and exclusion criteria. Inclusion criteria include all symptomatizing patients following supracervical hysterectomy, of any age, of any complaints. The exclusion criteria were patients with total hysterectomy, hysterectomies for malignant indications, and refusal to participate. - Methods: All patients' demographic data, history, indication of hysterectomy, duration since operation, postoperative complications and their main complaint. Intervention: under general anesthesia cervical biopsy (4 quadrants) were taken from all patients and was sent for histopathological examinations.

Recruitment information / eligibility
Status Completed
Enrollment 88
Est. completion date January 31, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender Female
Age group 40 Years and older
Eligibility Inclusion Criteria: - all symptomatizing patients following supracervical hysterectomy, Exclusion Criteria: - with total hysterectomy, - hysterectomies for malignant indications, - refusal to participate.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Cervical biopsy
4 quadrant biopsy

Locations
Country Name City State
Egypt Ayman Shehata Dawood Tanta Gharbia

Sponsors (1)
Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Detection of cervical neoplasia or cancer incidence Detection of number of cases diagnosed with cervical Cervical intraepithelial neoplasia, or malignancy by histopathological examination 1 year
Primary Detection of chronic cervicitis incidence Detection of number of cases diagnosed with inflammatory cells and other markers of inflammation 1 year
See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT00193739 - Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix Phase 3
Not yet recruiting NCT04999696 - Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer N/A
Completed NCT02309658 - Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Phase 2
Completed NCT00193752 - Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix N/A
Recruiting NCT00154479 - The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus N/A
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Not yet recruiting NCT06147960 - Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Completed NCT05149248 - Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Phase 2/Phase 3
Completed NCT00191100 - Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Phase 3
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Recruiting NCT05742711 - Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients N/A
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Active, not recruiting NCT05709730 - Follow-up of Cell Changes in the Cervix
Completed NCT00193791 - Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix N/A
Withdrawn NCT02312804 - Ph Ib/BGJ398/Cervix and Other Solid Tumors Phase 1
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Completed NCT00193804 - A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix